Fruquintinib has emerged as a specific VEGFR3/FLT4/CD310 inhibitor that potently inhibits angiogenesis and tumor growth in preclinical models (32) and clinical trials (58) of colon carcinoma, with recent approvals for its use as a third-line therapy in China, the USA, Canada, and several European countries. This evidence concerns the gene FLT4 and neoplasm.